Hyponatremia: Practice Essentials, Pathophysiology, Etiology (original) (raw)

Overview

Practice Essentials

Hyponatremia—defined as a serum sodium concentration of less than 135 mEq/L—is the most commonly encountered and important electrolyte imbalance that can be seen in isolation or, as is most often the case, as a complication of other medical illnesses (eg, heart failure, liver failure, kidney failure, pneumonia, cancer). [1] The normal serum sodium concentration is 135-145 mEq/L. Hyponatremia is classified in adults according to serum sodium concentration, as follows [2] :

Correction of hyponatremia varies according to its source, its severity, and its duration. In patients whose hyponatremia has a known duration of > 48 hours, treatment must be calibrated to avoid osmotic demyelination syndrome (ODS), which may result from overly rapid correction. [3]

Signs and symptoms

Symptoms range from nausea and malaise, in persons with mild reduction in the serum sodium, to lethargy, decreased level of consciousness, headache, and (with severe hyponatremia) seizures and coma. Overt neurologic symptoms most often are due to very low serum sodium levels (usually < 115 mEq/L), resulting in intracerebral osmotic fluid shifts and brain edema.

Hyponatremia can be classified according to effective osmolality, as follows:

Hypotonic hyponatremia can be further subclassified according to volume status, as follows:

See Presentation for more detail.

Diagnosis

Three laboratory tests are essential in the evaluation of patients with hyponatremia: serum osmolality, urine osmolality, and urinary sodium concentration. Together with the history and the physical examination, those tests help to establish the primary underlying etiologic mechanism in an algorithmic fashion.

Serum osmolality

Serum osmolality readily differentiates true hyponatremia (hypotonic hyponatremia) from pseudohyponatremia. The latter may be secondary to hyperlipidemia or hyperproteinemia (isotonic hyponatremia), or may be hypertonic hyponatremia associated with elevated levels of glucose, mannitol, glycine (posturologic or postgynecologic procedure), sucrose, or maltose (contained in IgG formulations).

Urine osmolality

Urine osmolality helps differentiate between conditions associated with the presence or absence of antidiuretic hormone (ADH), also called arginine vasopressin (AVP). A dilute urine (urine osmolality < 100 mOsm/kg) and hypotonic hyponatremia generally results from conditions that overwhelm the kidney’s capacity to excrete free water (as in primary polydipsia) or conditions that truncate the amount of free water that can be excreted, typically due to low solute load (as in tea and toast diet). A urine osmolality greater than 100 mOsm/kg indicates impaired ability of the kidneys to dilute the urine, usually due to physiologic or non-physiologic secretion of ADH. Some uncommon conditions may result in either low or high urinary osmolality, depending on the treatment initiated.

Urinary sodium concentration

Urinary sodium concentration helps to differentiate hyponatremia secondary to hypovolemia or ineffective intravascular volume status from syndrome of inappropriate antidiuretic hormone secretion (SIADH). In SIADH and salt-wasting syndrome the urine sodium is greater than 20-40 mEq/L. In hypovolemia or ineffective intravascular volume status, the urine sodium typically measures less than 20 mEq/L. However, if sodium intake in a patient with SIADH or salt-wasting happens to be low, then urine sodium may fall below 20 mEq/L.

See Workup for more detail.

Management

Hypotonic hyponatremia accounts for most clinical cases of hyponatremia and requires free water restriction. The treatment of hypertonic hyponatremia and pseudo-hyponatremia is directed at the underlying disorder, in the absence of symptoms.

Acute hyponatremia (duration < 48 hours) can be safely corrected more quickly than chronic hyponatremia. The rate of correction for chronic hyponatremia (duration of > 48 hours or unknown) should be tailored according to the severity of the hyponatremia so as to avoid overcorrection and risk of ODS, but should be limited to 4-8 mEq/L per 24 hours.

Intravenous fluids and water restriction

Patients with overt symptoms (eg, seizures, severe neurologic deficits) and generally those with severe hyponatremia should be treated with a hypertonic (3%) saline bolus to increase serum sodium concentration and mitigate their symptoms. In patients with moderate symptoms, a slow infusion of hypertonic saline can be considered. Patients who are asymptomatic or have mild symptoms will rarely require hypertonic saline.

Administer isotonic saline to patients who are hypovolemic to replace the contracted intravascular volume. Patients with hypovolemia secondary to diuretics may also need potassium repletion. Note that potassium, like sodium, is osmotically active.

Treat patients who are hypervolemic with fluid restriction, with or without loop diuretics, and correction of the underlying condition. The use of a vasopressin V2 receptor antagonist may be considered as second-line therapy.

For asymptomatic patients with euvolemic hyponatremia, free-water restriction is generally the treatment of choice. There is no role for hypertonic saline in these patients.

Pharmacologic treatment

Two vasopressin receptor antagonists, tolvaptan (Samsca) and conivaptan (Vaprisol), are approved for treatment of euvolemic and hypervolemic hyponatremia.

Tolvaptan, an orally administered selective vasopressin V2 receptor antagonist, is indicated for hypervolemic and euvolemic hyponatremia. It can be used for hyponatremia associated with congestive heart failure and SIADH and must be initiated or reinitiated in the hospital.

Conivaptan, an intravenously administered V1A and V2 vasopressin receptor antagonist, is currently unavailable in the United States due to a shortage. It is approved for use in the hospital setting for euvolemic and hypervolemic hyponatremia. It is contraindicated in hypovolemic patients.

Additional options include the following:

See Treatment and Medication for more detail.

eMedicine Logo

Pathophysiology

Hypo-osmolality (serum osmolality < 275 mOsm/kg) always indicates excess total body water relative to body solutes or excess water relative to solute in the extracellular fluid (ECF), as water moves freely between the intracellular and the extracellular compartments. This imbalance can be due to solute depletion, solute dilution, or a combination of both.

Under normal conditions, renal handling of water is sufficient to excrete as much as 15-20 L of free water per day. Further, the body's response to a decreased osmolality is decreased thirst. Thus, hyponatremia can occur only when some condition impairs normal free-water excretion.

Generally, hyponatremia is of clinical significance when it reflects a drop in the serum osmolality (ie, hypotonic hyponatremia), which is measured directly via osmometry or is calculated as 2(Na) mEq/L + serum glucose (mg/dL)/18 + BUN (mg/dL)/2.8. Note that urea is not an ineffective osmole, so when the urea levels are very high (as in azotemia), the measured osmolality should be corrected for the contribution of urea (measured serum osmolality – BUN (mg/dL)/2.8).

The recommendations for treatment of hyponatremia rely on the current understanding of central nervous system (CNS) adaptation to an altered serum osmolality. [4] In the setting of an acute drop in the serum osmolality, neuronal cell swelling occurs due to the water shift from the extracellular space to the intracellular space (ie, Starling forces). Swelling of the brain cells elicits the following two osmoregulatory responses:

Therefore, correction of hyponatremia must take into account the chronicity of the condition. Acute hyponatremia (duration < 48 h) can be corrected more quickly than chronic hyponatremia. Most individuals who present with symptomatic hyponatremia (as opposed to those who develop hyponatremia in an inpatient setting) have had hyponatremia for some time, so their condition is chronic, and correction should proceed accordingly. Overly rapid correction of serum sodium levels in these individuals can precipitate a severe neurologic complication, ODS. Consequently, when the duration of hyponatremia is uncertain, the condition should be considered chronic.

eMedicine Logo

Etiology

Although the differential diagnosis is quite broad, most hyponatremia can be classified as hypertonic, normotonic, or hypotonic in origin.

Hypertonic hyponatremia

Patients with hypertonic hyponatremia often have normal total body sodium levels but a dilutional drop in the measured serum sodium due to the presence of osmotically active molecules in the serum, which causes a water shift from the intracellular compartment to the extracellular compartment.

Glucose reduces the serum sodium level by 1.6 mEq/L for each 100 mg/dL of serum glucose greater than 100 mg/dL. This relationship is nonlinear, with greater reduction in plasma sodium concentrations with glucose concentrations over 400 mg/dL, so a 2.4 mEq/L reduction in sodium for each 100 mg/dL increase in glucose over 100 mg/dL is a more accurate correction factor when the glucose is greater than 400 mg/dL. [6]

Other examples of osmotically active molecules include mannitol (often used to treat brain edema) or maltose (used with intravenous immunoglobulin administration).

Normotonic hyponatremia

Severe hyperlipidemia and paraproteinemia can lead to low measured serum sodium concentrations with normal serum osmolality. Normally, water comprises 92-94% of plasma volume. The plasma water fraction falls with an increase in fats and proteins. The measured sodium concentration in the total plasma volume is respectively reduced, although the plasma sodium concentration and plasma osmolality are unchanged. This artifactual low sodium (so-called pseudohyponatremia) is secondary to measurement by flame photometry. It can be avoided by direct ion-selective electrode measurement. Another cause of pseudohyponatremia is seen in patients with cholestatic jaundice secondary to the presence of low-density lipoprotein, lipoprotein X, which can be detected by lipoprotein electrophoresis. [7]

Hyponatremia after transurethral resection of the prostate (TURP) or hysteroscopy is caused by absorption of glycine, sorbitol, or mannitol contained in nonconductive flushing solutions used for those procedures. The degree of hyponatremia is related to the quantity and rate of fluid absorbed. The plasma osmolality is also variable and changes over time. The presence of a relatively large osmolal gap due to excess organic solute is diagnostic in the appropriate clinical setting.

Hemodialysis, which will correct the hyponatremia and remove glycine and its toxic metabolites, can be used in patients with end-stage renal disease. Use of isotonic saline as an irrigant instead of glycine with the new bipolar resectoscope for TURP in high-risk patients (those with large prostates that require lengthy resection) can avoid this complication, making this disorder more a diagnosis of the past. [8]

Hypotonic hyponatremia

Hypotonic hyponatremia always reflects the inability of the kidneys to handle the excretion of free water to match the intake. Hypotonic hyponatremia with a urinary osmolality > 100 mOsm/kg (due to presence of inappropriate ADH) can be divided pathophysiologically into the following categories, according to the effective intravascular volume: hypervolemic, euvolemic, and hypovolemic. These clinically relevant groupings aid in determination of likely underlying etiology and guide treatment.

Hypervolemic hypotonic hyponatremia

This is characterized by clinically detectable edema or ascites that signifies an increase in total body water and sodium. Paradoxically, however, a decrease in the effective circulating volume, critical for tissue perfusion, stimulates the same pathophysiologic mechanism of impaired water excretion by the kidney that is observed in hypovolemic hypotonic hyponatremia. Commonly encountered examples include liver cirrhosis, congestive heart failure, nephrotic syndrome, and severe hypoproteinemia (albumin level < 1.5-2 g/dL).

Normovolemic (euvolemic) hypotonic hyponatremia

This is a very common cause of hyponatremia in hospitalized patients. It is associated with non-osmotic and non–volume-related ADH secretion (ie, SIADH) secondary to a variety of clinical conditions, including the following:

Some of the common medications associated with SIADH are as follows:

In those circumstances, the ability of the kidney to dilute urine in the setting of serum hypotonicity is reduced.

Hyponatremia is a relatively common adverse effect of desmopressin, a vasopressin analogue that acts as a pure V2 agonist and is used in the treatment of central diabetes insipidus, von Willebrand disease, nocturia in adults, and enuresis in children. Patients receiving desmopressin require regular monitoring of serum sodium levels. [12]

The diagnostic criteria for SIADH are as follows:

Urinary sodium concentrations are also typically greater than 20 mEq/L on a normal salt diet, as sodium excretion will reflect dietary sodium intake. Serum uric acid levels are generally reduced; this is due to reduced tubular uric acid reabsorption, which parallels the decrease in proximal tubular sodium reabsorption associated with central volume expansion. These findings are also found in a renal salt-wasting process. This similarity makes the differentiation between salt wasting and SIADH difficult except that in renal salt wasting, one would expect to find a hypovolemic state and possibly hypotension.

Reset osmostat is another important, but rare, cause of normovolemic hypotonic hyponatremia. This may occur in the elderly and during pregnancy. These patients regulate their serum osmolality around a reduced set point; however, in contrast to patients with SIADH (who also have a downward resetting of the osmotic threshold for thirst), [13] they are able to dilute their urine in response to a water load to keep the serum osmolality around the preset low point.

Severe hypothyroidism (unknown mechanism, possibly secondary to low cardiac output and glomerular filtration rate) and adrenal insufficiency are also associated with non-osmotic vasopressin release and impaired sodium reabsorption, leading to hypotonic hyponatremia. Hyponatremia associated with cortisol deficiency, such as primary or secondary hypoadrenalism, commonly presents subtly and may go undiagnosed. A random cortisol level check, especially in acute illness, can be misleading if the level is normal (when it should be high). Testing for adrenal insufficiency and hypothyroidism should be part of the hyponatremia workup, as the disorders respond promptly to hormone replacement.

Hospitalized patients who are infected with human immunodeficiency virus (HIV) have a high incidence of hyponatremia. [14] In these cases, hyponatremia is usually due to disorders associated with an increased ADH level:

Hypovolemic hypotonic hyponatremia

This usually indicates concomitant solute depletion, with patients presenting with orthostatic symptoms. The pathophysiology underlying hypovolemic hypotonic hyponatremia is complex and involves the interplay of carotid baroreceptors, the sympathetic nervous system, the renin-angiotensin system, antidiuretic hormone (ADH; vasopressin) secretion, and renal tubular function. In the setting of decreased intravascular volume (eg, severe hemorrhage or severe volume depletion secondary to GI or renal loss or diuretic use) owing to a decreased stretch on the baroreceptors in the great veins, aortic arch, and carotid bodies, an increased sympathetic tone to maintain systemic blood pressure generally occurs.

This increased sympathetic tone, along with decreased renal perfusion secondary to intravascular volume depletion, results in increased renin and angiotensin secretion. This, in turn, results in increased sodium absorption in the proximal tubules of the kidney via angiotensin II and consequent decreased delivery of solutes to distal diluting segments, causing an impairment of renal free water excretion. There also is a concomitant increase in serum ADH production that further impairs free water excretion. Because angiotensin is also a very potent stimulant of thirst, free water intake is increased inappropriately at the same time, when water excretion is limited. Together, these changes lead to hyponatremia.

Cerebral salt wasting (CSW) is seen with intracranial disorders, such as subarachnoid hemorrhage, carcinomatous or infectious meningitis, metastatic carcinoma, traumatic brain injury, and pituitary disorders, but especially after neurologic procedures. [15, 16] Disruption of sympathetic neural input into the kidney, which normally promotes salt and water reabsorption in the proximal nephron segment through various indirect and direct mechanisms, might cause renal salt wasting, resulting in reduced plasma volume.

Plasma renin and aldosterone levels fail to rise appropriately in patients with CSW despite a reduced plasma volume because of disruption of the sympathetic nervous system. In addition, the release of one or more natriuretic factors could also play a role in the renal salt wasting seen in CSW. Volume depletion leads to an elevation of plasma vasopressin levels and impaired free water excretion.

Distinguishing between CSW and SIADH can be challenging, because there is considerable overlap in the clinical presentation. [17] Vigorous salt replacement is required in patients with CSW, whereas fluid restriction is the treatment of choice in patients with SIADH. Infusion of isotonic saline to correct the volume depletion is usually effective in reversing the hyponatremia in CSW, since euvolemia will suppress the release of ADH. The disorder is usually transient, with resolution occurring within 3-4 weeks of disease onset.

Salt-wasting nephropathy causing hypovolemic hyponatremia may rarely develop in a range of renal disorders (eg, interstitial nephropathy, medullary cystic disease, polycystic kidney disease, partial urinary obstruction) with low salt intake.

Another rare cause of hypovolemic hyponatremia secondary to solute loss in body fluid is high biliary fluid loss due to external biliary drainage—for example, in the setting of acalculous cholecystitis.The drained biliary fluid has a high sodium concentration, ranging between 122-164 mmol/L. The significant sodium loss in bile fluid results in hypotension and renal free-water retention in response to increased ADH secretion. [18]

Diuretics may induce hypovolemic hyponatremia. Note that thiazide diuretics, in contrast to loop diuretics, impair the diluting mechanism without limiting the concentrating mechanism, thereby impairing the ability to excrete a free-water load. Thus, thiazides are more prone to causing hyponatremia than are loop diuretics. This is particularly so in elderly persons, who already have impaired diluting ability.

Other causes

There are other causes that do not fit in any of the above categories and may or may not be associated with elevated levels of ADH or may simply overwhelm the capacity of the kidneys to properly excrete excess water.

The most common precipitant of hyponatremia in patients after surgery is the iatrogenic infusion of hypotonic fluids. [19] Inappropriate administration of hypotonic intravenous fluids after surgery increases the risk of hyponatremia in these vulnerable patients, who retain water due to non-osmotic release of ADH, which can be elevated for a few days after most surgical procedures.

In severely malnourished individuals with a low-protein but high-water diet, diminished intake of solutes limits the ability of the kidney to handle free water. This is similar to the known condition of beer potomania, which occurs in individuals whose main source of calories is alcohol. [20] In these patients, the urinary osmolality will typically be < 100 mOsm/kg.

Compulsive intake of large amounts of water exceeding the diluting capacity of the kidneys (> 20 L/d), despite a normal solute intake of 600-900 mOsm/d can result in hyponatremia. These patients will have a maximally dilute urine (urinary osmolality < 100 mOsm/kg), unlike those with SIADH. In primary polydipsia, there is a defect in thirst regulation due to a psychiatric illness, with different abnormalities in ADH regulation identified in psychotic patients. Transient stimulation of ADH release during acute psychotic episodes, an increase in the net renal response to ADH, downward resetting of the osmostat, and antipsychotic medication may contribute. Limiting water intake will rapidly raise the plasma sodium concentration as the excess water is readily excreted in dilute urine. [21]

Acute hyponatremia is not an uncommon occurrence in ultra-endurance athletes and marathon runners, with women being at higher risk. [22] The strongest single predictor of hyponatremia in these cases is weight gain during the race correlating with excessive fluid intake. Longer race time and lower body mass index extremes are also associated with hyponatremia, whereas the composition of fluids consumed (plain water rather than sports drinks containing electrolytes) is not. Oxidization of glycogen and triglyceride during a race is associated with the production of "bound" water, which then becomes an endogenous, electrolyte-free water infusion contributing to hyponatremia induced by water ingestion in excess of water losses.

It should be noted that some runners who collapse during a race are normonatremic or even hypernatremic, [23] making blanket recommendations difficult. However, fluid intake to the point of weight gain should be avoided. [24] Athletes should rely on thirst as their guide for fluid replacement and avoid global recommendations for water intake. Symptomatic patients with documented hyponatremia should receive 100 mL of 3% sodium chloride over 10 minutes in the field before transportation to hospital. This maneuver should raise the plasma sodium concentration an average of 2-3 mEq/L. [25]

By inhibiting prostaglandin formation, NSAID use may increase the risk of hyponatremia developing during strenuous exercise. Prostaglandins have a natriuretic effect. Prostaglandin depletion increases NaCl reabsorption in the thick ascending limb of Henle (ultimately increasing medullary tonicity) whereby ADH action in the collecting duct can lead to increased free water retention. [26]

Symptomatic and potentially fatal hyponatremia can develop with rapid onset after ingestion of the amphetamine derivative methylenedioxymethamphetamine (MDMA; ecstasy, Molly). [27] A marked increase in water intake via direct thirst stimulation, as well as inappropriate secretion of ADH, contributes to the hyponatremia seen with even a low dose of this drug.

Nephrogenic syndrome of inappropriate antidiuresis (NSIAD) is an SIADH-like clinical and laboratory picture seen in male infants who present with neurologic symptoms secondary to hyponatremia in the setting of undetectable plasma arginine vasopressin (AVP) levels. This hereditary disorder is secondary to a gain-of-function mutation in the V2 vasopressin receptor, resulting in constitutive activation of the receptor with elevated cyclic adenosine monophosphate (cAMP) production in the collecting duct principal cells.

Treatment of NSIAD poses a challenge. Water restriction improves serum sodium levels and osmolality in infants, but it limits calorie intake in formula-fed infants. The use of demeclocycline or lithium is potentially limited due to their adverse effects. The current therapy of choice is fluid restriction and the use of oral urea to induce obligatory free water excretion via osmotic diuresis. [28]

Hyponatremic-hypertensive syndrome, a rare condition, consists of severe hypertension associated with renal artery stenosis, hyponatremia, hypokalemia, severe thirst, and kidney dysfunction characterized by natriuresis, hypercalciuria, renal glycosuria, and proteinuria. Angiotensin-mediated thirst coupled with non-osmotic release of vasopressin provoked by angiotensin II and/or hypertensive encephalopathy are likely mechanisms for this syndrome. Sodium depletion due to pressure natriuresis and potassium depletion due to hyperaldosteronism with high plasma renin activity are also likely to play a role in the pathogenesis of hyponatremia. The abnormalities resolve with correction of the renal artery stenosis. [29]

eMedicine Logo

Epidemiology

United States

The incidence of hyponatremia depends largely on the patient population and the criteria used to establish the diagnosis. Among hospitalized patients, 15-20% have a serum sodium level of < 135 mEq/L, while only 1-4% have a serum sodium level of less than 130 mEq/L. The prevalence of hyponatremia is lower in the ambulatory setting.

The US armed forces reported 1579 incident diagnoses of exertional hyponatremia among active service members from 2003 through 2018, for a crude overall incidence rate of 7.2 cases per 100,000 person-years. Cases occurred both in training facilities and theaters of war. Diagnosis and treatment without hospitalization was accomplished in 86.3% of cases. [30]

Mortality/morbidity

Severe hyponatremia (< 125 mEq/L) has a high mortality rate. In patients whose serum sodium level falls below 105 mEq/L, and especially in persons with alcohol use disorder, the mortality is over 50%. [31]

In patients with acute ST-elevation myocardial infarction (MI), the presence of hyponatremia on admission or early development of hyponatremia is an independent predictor of 30-day mortality, and the prognosis worsens with the severity of hyponatremia. [32] In hospitalized survivors of acute MI, the presence of hyponatremia at discharge is an independent predictor of 12-month mortality. [33]

Similarly, cirrhotic patients with persistent ascites and a low serum sodium level who are awaiting liver transplantation have a high mortality risk despite low- severity Model for End-Stage Liver Disease (MELD) scores (see the MELD Score calculator). The independent predictors—ascites and hyponatremia—are findings indicative of hemodynamic decompensation. [34, 35, 36]

In patients with chronic kidney disease, hyponatremia and hypernatremia are associated with an increased risk for all-cause mortality and for deaths unrelated to cardiovascular problems or malignancy. Hyponatremia is also linked to an increased risk for cardiovascular- and malignancy-related mortality in these patients. [37]

Race-, sex-, and age-related demographics

Hyponatremia affects all races.

No sexual predilection exists for hyponatremia. However, symptoms are more likely to occur in young women than in men. Hyponatremia is more common in elderly persons partially because of higher rate of comorbid conditions (eg, heart, liver, or kidney failure) that can lead to hyponatremia.

eMedicine Logo

Prognosis

The prognosis for patients with hyponatremia is predicated upon the underlying etiology. Hyponatremia in patients with cancer is associated with extended hospital stays and higher mortality rates; however, whether long-term correction of hyponatremia would improve these outcomes is unclear. [38]

In patients with end-stage renal disease who are receiving hemodialysis or peritoneal dialysis, evidence suggests that the risk of death rises with incrementally lower sodium levels. Causes of hyponatremia-related mortality in the dialysis population remain uncertain, but possibilities include central nervous system toxicity, falls and fractures, infection-related complications, and impaired cardiac function. [39]

A meta-analysis of 15 studies encompassing 13,816 patients found that any improvement in hyponatremia was associated with a reduced risk of overall mortality (odds ratio [OR]=0.57). With the eight studies that reported a threshold for serum sodium improvement to > 130 mmol/L, the association was even stronger (OR=0.51). The reduction in mortality risk persisted at 12-month follow-up (OR=0.55). Reduced mortality was more evident in older patients and in patients with lower serum sodium levels at enrollment. [40]

eMedicine Logo

Patient Education

Patients who are to be treated with fluid restriction often require education regarding the free-water content of foods and an explanation of the need to limit the intake of liquids to a predetermined level.

eMedicine Logo

  1. Adrogué HJ, Tucker BM, Madias NE. Diagnosis and Management of Hyponatremia: A Review. JAMA. 2022 Jul 19. 328 (3):280-291. [QxMD MEDLINE Link].
  2. [Guideline] Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013 Oct. 126 (10 Suppl 1):S1-42. [QxMD MEDLINE Link].
  3. Sterns RH, et al; PRONATREOUS Investigators. Treatment Guidelines for Hyponatremia: Stay the Course. Clin J Am Soc Nephrol. 2024 Jan 1. 19 (1):129-135. [QxMD MEDLINE Link].
  4. Gankam Kengne F. Adaptation of the Brain to Hyponatremia and Its Clinical Implications. J Clin Med. 2023 Feb 21. 12 (5):R1595-9. [QxMD MEDLINE Link].
  5. Sterns RH. Treatment of Severe Hyponatremia. Clin J Am Soc Nephrol. 2018 Apr 6. 13 (4):641-649. [QxMD MEDLINE Link].
  6. Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med. 1999 Apr. 106 (4):399-403. [QxMD MEDLINE Link].
  7. Song L, Hanna RM, Nguyen MK, Kurtz I, Wilson J. A Novel Case of Pseudohyponatremia Caused by Hypercholesterolemia. Kidney Int Rep. 2019 Mar. 4 (3):491-493. [QxMD MEDLINE Link]. [Full Text].
  8. Issa MM, Young MR, Bullock AR, Bouet R, Petros JA. Dilutional hyponatremia of TURP syndrome: a historical event in the 21st century. Urology. 2004 Aug. 64 (2):298-301. [QxMD MEDLINE Link].
  9. Yang CH, Lin YC, Chou PH, Chen HC, Chan CH. A Case Report of Late Onset Mania Caused by Hyponatremia in a Patient With Empty Sella Syndrome. Medicine (Baltimore). 2016 Feb. 95 (6):e2629. [QxMD MEDLINE Link].
  10. Sterns RH. The syndrome of inappropriate antidiuretic hormone secretion of unknown origin. Am J Kidney Dis. 1999 Jan. 33 (1):161-3; discussion 163-5. [QxMD MEDLINE Link].
  11. Bischoff J, Fries C, Heer A, Hoffmann F, Meyer C, Landsberg J, et al. It's Not Always SIAD: Immunotherapy-Triggered Endocrinopathies Enter the Field of Cancer-Related Hyponatremia. J Endocr Soc. 2022 May 1. 6 (5):bvac036. [QxMD MEDLINE Link]. [Full Text].
  12. Pham PC, Pham PM, Pham PT. Vasopressin excess and hyponatremia. Am J Kidney Dis. 2006 May. 47 (5):727-37. [QxMD MEDLINE Link]. [Full Text].
  13. Smith D, Moore K, Tormey W, Baylis PH, Thompson CJ. Downward resetting of the osmotic threshold for thirst in patients with SIADH. Am J Physiol Endocrinol Metab. 2004 Nov. 287 (5):E1019-23. [QxMD MEDLINE Link].
  14. Glassock RJ, Cohen AH, Danovitch G, Parsa KP. Human immunodeficiency virus (HIV) infection and the kidney. Ann Intern Med. 1990 Jan 1. 112 (1):35-49. [QxMD MEDLINE Link].
  15. Palmer BF. Hyponatraemia in a neurosurgical patient: syndrome of inappropriate antidiuretic hormone secretion versus cerebral salt wasting. Nephrol Dial Transplant. 2000 Feb. 15 (2):262-8. [QxMD MEDLINE Link].
  16. Sherlock M, O'Sullivan E, Agha A, Behan LA, Owens D, Finucane F, et al. Incidence and pathophysiology of severe hyponatraemia in neurosurgical patients. Postgrad Med J. 2009 Apr. 85 (1002):171-5. [QxMD MEDLINE Link]. [Full Text].
  17. Palmer BF. Hyponatremia in patients with central nervous system disease: SIADH versus CSW. Trends Endocrinol Metab. 2003 May-Jun. 14 (4):182-7. [QxMD MEDLINE Link].
  18. Furey AT. Hyponatremia after choledochostomy and T tube drainage. Am J Surg. 1966 Dec. 112 (6):850-5. [QxMD MEDLINE Link].
  19. Skippen P, Adderley R, Bennett M, Cogswell A, Froese N, Seear M, et al. Iatrogenic hyponatremia in hospitalized children: Can it be avoided?. Paediatr Child Health. 2008 Jul. 13 (6):502-6. [QxMD MEDLINE Link].
  20. Thaler SM, Teitelbaum I, Berl T. "Beer potomania" in non-beer drinkers: effect of low dietary solute intake. Am J Kidney Dis. 1998 Jun. 31 (6):1028-31. [QxMD MEDLINE Link].
  21. Goldman MB, Luchins DJ, Robertson GL. Mechanisms of altered water metabolism in psychotic patients with polydipsia and hyponatremia. N Engl J Med. 1988 Feb 18. 318 (7):397-403. [QxMD MEDLINE Link].
  22. Danz M, Pöttgen K, Tönjes PM, Hinkelbein J, Braunecker S. Hyponatremia among Triathletes in the Ironman European Championship. N Engl J Med. 2016 Mar 10. 374 (10):997-8. [QxMD MEDLINE Link].
  23. Kratz A, Siegel AJ, Verbalis JG, Adner MM, Shirey T, Lee-Lewandrowski E, et al. Sodium status of collapsed marathon runners. Arch Pathol Lab Med. 2005 Feb. 129 (2):227-30. [QxMD MEDLINE Link].
  24. Almond CS, Shin AY, Fortescue EB, Mannix RC, Wypij D, Binstadt BA, et al. Hyponatremia among runners in the Boston Marathon. N Engl J Med. 2005 Apr 14. 352 (15):1550-6. [QxMD MEDLINE Link].
  25. [Guideline] Hew-Butler T, Almond C, Ayus JC, Dugas J, Meeuwisse W, Noakes T, et al. Consensus statement of the 1st International Exercise-Associated Hyponatremia Consensus Development Conference, Cape Town, South Africa 2005. Clin J Sport Med. 2005 Jul. 15 (4):208-13. [QxMD MEDLINE Link].
  26. Baker J, Cotter JD, Gerrard DF, Bell ML, Walker RJ. Effects of indomethacin and celecoxib on renal function in athletes. Med Sci Sports Exerc. 2005 May. 37 (5):712-7. [QxMD MEDLINE Link].
  27. Budisavljevic MN, Stewart L, Sahn SA, Ploth DW. Hyponatremia associated with 3,4-methylenedioxymethylamphetamine ("Ecstasy") abuse. Am J Med Sci. 2003 Aug. 326 (2):89-93. [QxMD MEDLINE Link].
  28. Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med. 2005 May 5. 352 (18):1884-90. [QxMD MEDLINE Link].
  29. Trivelli A, Ghiggeri GM, Canepa A, Oddone M, Bava G, Perfumo F. Hyponatremic-hypertensive syndrome with extensive and reversible renal defects. Pediatr Nephrol. 2005 Jan. 20 (1):102-4. [QxMD MEDLINE Link]. [Full Text].
  30. Update: Exertional hyponatremia, active component, U.S. Armed Forces, 2003-2018. MSMR. 2019 Apr. 26 (4):27-31. [QxMD MEDLINE Link].
  31. Chawla A, Sterns RH, Nigwekar SU, Cappuccio JD. Mortality and serum sodium: do patients die from or with hyponatremia?. Clin J Am Soc Nephrol. 2011 May. 6 (5):960-5. [QxMD MEDLINE Link].
  32. Shah V, Jahan N. Prognostic Significance of Hyponatremia in ST-elevation Myocardial Infarction/Heart Failure Patients. Cureus. 2019 Sep 16. 11 (9):e5673. [QxMD MEDLINE Link].
  33. Bae MH, Kim JH, Jang SY, Park SH, Lee JH, Yang DH, et al. Hyponatremia at discharge as a predictor of 12-month clinical outcomes in hospital survivors after acute myocardial infarction. Heart Vessels. 2017 Feb. 32 (2):126-133. [QxMD MEDLINE Link].
  34. Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004 Oct. 40 (4):802-10. [QxMD MEDLINE Link].
  35. Kim MY, Baik SK, Yea CJ, Lee IY, Kim HJ, Park KW, et al. Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis. Eur J Gastroenterol Hepatol. 2009 Nov. 21 (11):1241-6. [QxMD MEDLINE Link].
  36. Ginés P, Berl T, Bernardi M, Bichet DG, Hamon G, Jiménez W, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology. 1998 Sep. 28 (3):851-64. [QxMD MEDLINE Link].
  37. Huang H, Jolly SE, Airy M, Arrigain S, Schold JD, Nally JV, et al. Associations of dysnatremias with mortality in chronic kidney disease. Nephrol Dial Transplant. 2017 Jul 1. 32 (7):1204-1210. [QxMD MEDLINE Link]. [Full Text].
  38. Doshi SM, Shah P, Lei X, Lahoti A, Salahudeen AK. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis. 2012 Feb. 59 (2):222-8. [QxMD MEDLINE Link].
  39. Rhee CM, Ayus JC, Kalantar-Zadeh K. Hyponatremia in the Dialysis Population. Kidney Int Rep. 2019 Jun. 4 (6):769-780. [QxMD MEDLINE Link].
  40. Corona G, Giuliani C, Verbalis JG, Forti G, Maggi M, Peri A. Hyponatremia improvement is associated with a reduced risk of mortality: evidence from a meta-analysis. PLoS One. 2015. 10 (4):e0124105. [QxMD MEDLINE Link].
  41. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999 Aug 19. 341 (8):577-85. [QxMD MEDLINE Link]. [Full Text].
  42. Bettari L, Fiuzat M, Shaw LK, Wojdyla DM, Metra M, Felker GM, et al. Hyponatremia and long-term outcomes in chronic heart failure--an observational study from the Duke Databank for Cardiovascular Diseases. J Card Fail. 2012 Jan. 18 (1):74-81. [QxMD MEDLINE Link].
  43. Hew-Butler T, Loi V, Pani A, Rosner MH. Exercise-Associated Hyponatremia: 2017 Update. Front Med (Lausanne). 2017. 4:21. [QxMD MEDLINE Link].
  44. Lien YH. Antidepressants and Hyponatremia. Am J Med. 2018 Jan. 131 (1):7-8. [QxMD MEDLINE Link].
  45. Lu X, Wang X. Hyponatremia induced by antiepileptic drugs in patients with epilepsy. Expert Opin Drug Saf. 2017 Jan. 16 (1):77-87. [QxMD MEDLINE Link].
  46. Zenenberg RD, Carluccio AL, Merlin MA. Hyponatremia: evaluation and management. Hosp Pract (1995). 2010 Feb. 38 (1):89-96. [QxMD MEDLINE Link].
  47. Zeidel ML. Hyponatremia: mechanisms and newer treatments. Endocr Pract. 2010 Sep-Oct. 16 (5):882-7. [QxMD MEDLINE Link]. [Full Text].
  48. Silver SM, Kozlowski SA, Baer JE, Rogers SJ, Sterns RH. Glycine-induced hyponatremia in the rat: a model of post-prostatectomy syndrome. Kidney Int. 1995 Jan. 47 (1):262-8. [QxMD MEDLINE Link].
  49. Ruzek KA, Campeau NG, Miller GM. Early diagnosis of central pontine myelinolysis with diffusion-weighted imaging. AJNR Am J Neuroradiol. 2004 Feb. 25 (2):210-3. [QxMD MEDLINE Link].
  50. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant. 2014 Apr. 29 Suppl 2:i1-i39. [QxMD MEDLINE Link].
  51. George JC, Zafar W, Bucaloiu ID, Chang AR. Risk Factors and Outcomes of Rapid Correction of Severe Hyponatremia. Clin J Am Soc Nephrol. 2018 Jul 6. 13 (7):984-992. [QxMD MEDLINE Link].
  52. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000 May 25. 342 (21):1581-9. [QxMD MEDLINE Link]. [Full Text].
  53. Vachharajani TJ, Zaman F, Abreo KD. Hyponatremia in critically ill patients. J Intensive Care Med. 2003 Jan-Feb. 18 (1):3-8. [QxMD MEDLINE Link]. [Full Text].
  54. Perianayagam A, Sterns RH, Silver SM, Grieff M, Mayo R, Hix J, et al. DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia. Clin J Am Soc Nephrol. 2008 Mar. 3 (2):331-6. [QxMD MEDLINE Link].
  55. Krisanapan P, Vongsanim S, Pin-On P, Ruengorn C, Noppakun K. Efficacy of Furosemide, Oral Sodium Chloride, and Fluid Restriction for Treatment of Syndrome of Inappropriate Antidiuresis (SIAD): An Open-label Randomized Controlled Study (The EFFUSE-FLUID Trial). Am J Kidney Dis. 2020 Aug. 76 (2):203-212. [QxMD MEDLINE Link].
  56. Jovanovich AJ, Berl T. Where vaptans do and do not fit in the treatment of hyponatremia. Kidney Int. 2013 Apr. 83 (4):563-7. [QxMD MEDLINE Link].
  57. Spasovski G. Hyponatremia - Treatment standard 2024. Nephrol Dial Transplant. 2024 Jul 15. 4 (6):1149-55. [QxMD MEDLINE Link].
  58. Farmakis D, Filippatos G, Kremastinos DT, Gheorghiade M. Vasopressin and vasopressin antagonists in heart failure and hyponatremia. Curr Heart Fail Rep. 2008 Jun. 5 (2):91-6. [QxMD MEDLINE Link].
  59. FDA limits use of tolvaptan due to liver injury risk. Reactions Weekly 2013;1452(1):3-3. 2013.
  60. Yu J, Zheng SS, Liang TB, Shen Y, Wang WL, Ke QH. Possible causes of central pontine myelinolysis after liver transplantation. World J Gastroenterol. 2004 Sep 1. 10 (17):2540-3. [QxMD MEDLINE Link].
  61. MacMillan TE, Shin S, Topf J, Kwan JL, Weinerman A, Tang T, et al. Osmotic Demyelination Syndrome in Patients Hospitalized with Hyponatremia. NEJM Evid. 2023 Apr. 2 (4):EVIDoa2200215. [QxMD MEDLINE Link].
  62. Ayus JC, Moritz ML. Hyponatremia Treatment Guidelines - Have They Gone Too Far?. NEJM Evid. 2023 Apr. 2 (4):EVIDe2300014. [QxMD MEDLINE Link].
  63. Rondon-Berrios H, Tandukar S, Mor MK, Ray EC, Bender FH, Kleyman TR, et al. Urea for the Treatment of Hyponatremia. Clin J Am Soc Nephrol. 2018 Nov 7. 13 (11):1627-1632. [QxMD MEDLINE Link].
  64. Santos BC, Chevaile A, Hébert MJ, Zagajeski J, Gullans SR. A combination of NaCl and urea enhances survival of IMCD cells to hyperosmolality. Am J Physiol. 1998 Jun. 274 (6):F1167-73. [QxMD MEDLINE Link].
  65. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006 Nov 16. 355 (20):2099-112. [QxMD MEDLINE Link].
  66. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007 Mar 28. 297 (12):1319-31. [QxMD MEDLINE Link].

Author

Seyed Mehrdad Hamrahian, MD Associate Professor of Medicine (Nephrology), Sidney Kimmel Medical College of Thomas Jefferson University; Director of American Society of Hypertension-Designated Jefferson Hypertension Center; Medical Director, Jefferson Nephrology Outpatient Clinic; Medical Director, Jefferson Home Hemodialysis Program; Medical Director of Chronic Dialysis Unit, DaVita City Line Dialysis

Seyed Mehrdad Hamrahian, MD is a member of the following medical societies: American Heart Association, American Society of Nephrology

Disclosure: Nothing to disclose.

Coauthor(s)

Omar H Maarouf, MD Associate Professor of Medicine, Director of Renal Course, Division of Nephrology, Sidney Kimmel Medical College of Thomas Jefferson University; Director of Acute Dialysis Unit, Associate Program Director of Renal Fellowship, Jefferson Renal Associates, Thomas Jefferson University Hospital

Omar H Maarouf, MD is a member of the following medical societies: American Society of Nephrology, National Kidney Foundation

Disclosure: Nothing to disclose.

Federico J Teran, MD Assistant Professor of Clinical Medicine, Section of Nephrology and Hypertension, Tulane University School of Medicine; Chief of Nephrology, VA Southeast Louisiana Healthcare System

Federico J Teran, MD is a member of the following medical societies: American College of Physicians, American Medical Association, American Society of Nephrology, Louisiana State Medical Society, National Kidney Foundation, Renal Physicians Association

Disclosure: Nothing to disclose.

Eric E Simon, MD Professor of Medicine, Chief, Section of Nephrology and Hypertension, Tulane University School of Medicine; Director, Nephrology Training, Medical Director, Dialysis Clinic, Inc, Canal Street

Eric E Simon, MD is a member of the following medical societies: American Federation for Medical Research, American Heart Association, American Physiological Society, American Society for Cell Biology, American Society of Nephrology, Central Society for Clinical and Translational Research, International Society of Nephrology, National Kidney Foundation, Phi Beta Kappa, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Eleanor Lederer, MD, FASN Professor of Medicine, Chief, Nephrology Division, Director, Nephrology Training Program, Director, Metabolic Stone Clinic, Kidney Disease Program, University of Louisville School of Medicine; Consulting Staff, Louisville Veterans Affairs Hospital

Eleanor Lederer, MD, FASN is a member of the following medical societies: American Association for the Advancement of Science, American Society for Bone and Mineral Research, American Society of Nephrology, American Society of Transplantation, International Society of Nephrology, Kentucky Medical Association, National Kidney Foundation

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: American Society of Nephrology
Received income in an amount equal to or greater than $250 from: Healthcare Quality Strategies, Inc.

Chief Editor

Vecihi Batuman, MD, FASN Professor of Medicine, Section of Nephrology-Hypertension, Deming Department of Medicine, Tulane University School of Medicine

Vecihi Batuman, MD, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.